<DOC>
	<DOCNO>NCT01276912</DOCNO>
	<brief_summary>- Pre-diabetes significant risk factor development type 2 diabetes , well macrovascular microvascular complication . - Previous study show 50 % loss islet B-cell function even Pre-diabetes phase . The early insulin therapy pre-diabetes may strategy prevent metabolic disorder cardiovascular disease . - The objective study find initial insulin glargine intervention pre-diabetes ( IGT /or IFG ) could strategy prevent type 2 Diabetes . - Pre-diabetes subject receive insulin glargine therapy dosage adjust get FBG ≤ 5.3mmol / L goal . Insulin glargine treatment maintain three month thereafter find prevent diabetes .</brief_summary>
	<brief_title>Study TO Prevent Diabetes With Short-term Insulin Glargine Only</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . All participant voluntary write inform consent 2 week enrollment . 2 . Fasting Blood Glucose &gt; = 5.6mmol/L &lt; 7.0mmol/L , HbA1c &gt; = 5.7 % &lt; 6.5 % . 3 . Both male female age &gt; = 25 ≤ 65 year . 4 . Participants ability use selfmonitoring device measure blood glucose level practice selfinsulin injection . 5 . Have ability willingness complete study log questionnaire . 6 . Pregnancy test childbearing age woman negative , agree adopt contraceptive measure study process . 1 . With previous diagnosis diabetes application hypoglycemic drug . 2 . Preliminary screen fast plasma glucose lever ≥7.0mmol/L &lt; 5.6mmol/L . 3 . Preliminary screen HbA1c result HbA1c &lt; 5.7 % ≥ 6.5 % . 4 . Receiving cancer treatment past 5 year . 5 . Preliminary diagnostic antiHIV test result positive , serological testing . 6 . People active tuberculosis . 7 . Persons hospitalize heart disease receive treatment measure ( coronary artery bypass graft CABG , percutaneous transluminal coronary angioplasty PTCA ) , include diagnostic measure ( percutaneous coronary angiography ) past 6 month . 8 . Cardiac function evaluate New York Heart Association criterion ( NYHA ) ≥ 3 cardiac function level 9 . Uncontrolled high blood pressure systolic blood pressure &gt; 180mmHg diastolic blood pressure &gt; 105mmHg treatment . 10 . Stroke transient ischemic attack episode past 6 month . 11 . With chronic hepatitis active liver disease , serum AST ALT 2.5 time upper limit normal . 12 . Male serum creatinine ≥ 124μmol/L ( 1.4mg/dL ) ; Female serum creatinine ≥ 115μmol/L ( 1.3mg/dL ) . 13 . Systemic glucocorticoid application , local , eye , inhalation application . 14 . Anemia : male hematocrit &lt; 36.0 % ; female &lt; 33.0 % . 15 . Other chronic disease may lead expected life le 6 year condition may affect life expectancy . 16 . Mental disorder history . 17 . Alcohol consumption ( average 50g high spirit drink 100g low spirit drink ) drug abuse . 18 . Unable unwilling sign inform consent . 19 . Can communicate contact clinical staff . 20 . Unwilling receive insulin injection therapy conduct selfmonitoring blood glucose . 21 . Unsatisfied control thyroid disease subject suffer thyroid disease receive antithyroid drug thyroid hormone treatment , show sensitive TSH abnormality ( except patient low TSH history thyroid tumor thyroid cancer receive inhibitor treatment ) . 22 . Any factor may affect compliance adverse event report research program .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>